Upstream Bio, Inc./$UPB
13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX
About Upstream Bio, Inc.
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.
Ticker
$UPB
Sector
Primary listing
Employees
52
Headquarters
Website
UPB Metrics
BasicAdvanced
$1.3B
-
-$3.02
-
-
Price and volume
Market cap
$1.3B
52-week high
$24.00
52-week low
$5.14
Average daily volume
436K
Financial strength
Current ratio
38.272
Quick ratio
36.098
Long term debt to equity
0.208
Total debt to equity
0.382
Profitability
EBITDA (TTM)
-121.423
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-3,836.58%
Operating margin (TTM)
-4,464.60%
Revenue per employee (TTM)
$50,000
Management effectiveness
Return on assets (TTM)
-22.85%
Return on equity (TTM)
-32.49%
Valuation
Price to revenue (TTM)
337.972
Price to book
3.1
Price to tangible book (TTM)
3.1
Price to free cash flow (TTM)
-8.035
Free cash flow yield (TTM)
-12.45%
Free cash flow per share (TTM)
-2.935
Growth
Revenue change (TTM)
22.60%
Earnings per share change (TTM)
-83.14%
Bulls say / Bears say
Upstream Bio expanded its clinical pipeline into a third major respiratory indication by dosing the first patient in its global Phase 2 VENTURE trial for verekitug in moderate-to-severe COPD, diversifying its development risk beyond CRSwNP and severe asthma.
With $393.6 million in cash and short-term investments as of June 30, 2025, Upstream Bio has secured funding through 2027, reducing near-term financing risk while advancing multiple Phase 2 programs.
Quantitative pharmacology modeling data presented at the EAACI Congress demonstrated verekitug’s potent and sustained TSLP receptor inhibition, reinforcing its differentiated mechanism and rapid, robust pharmacodynamic profile.
R&D expenses surged 168.8% year-over-year to $37.9 million in Q2 2025, driving net loss to $40 million and accelerating cash burn, which could pressure the company if clinical timelines slip.
As a single-asset company with all programs in Phase 2, Upstream Bio’s valuation is highly dependent on binary trial outcomes; failure in any of the CRSwNP, severe asthma or COPD readouts could severely erode its market value.
Tezepelumab, an approved TSLP inhibitor, has demonstrated a 98% reduction in nasal polyp surgery and an 88% reduction in corticosteroid use in Phase III CRSwNP trials, posing a significant competitive threat to verekitug’s market prospects.
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Upstream Bio, Inc. stock?
Upstream Bio, Inc. (UPB) has a market cap of $1.3B as of October 28, 2025.
What is the P/E ratio for Upstream Bio, Inc. stock?
The price to earnings (P/E) ratio for Upstream Bio, Inc. (UPB) stock is 0 as of October 28, 2025.
Does Upstream Bio, Inc. stock pay dividends?
No, Upstream Bio, Inc. (UPB) stock does not pay dividends to its shareholders as of October 28, 2025.
When is the next Upstream Bio, Inc. dividend payment date?
Upstream Bio, Inc. (UPB) stock does not pay dividends to its shareholders.
What is the beta indicator for Upstream Bio, Inc.?
Upstream Bio, Inc. (UPB) does not currently have a Beta indicator.